Zephyr AI, Inc., a MCLean. VA-based healthcare technology company committed to developing explainable Artificial Intelligence (AI) solutions for precision medicine, closed a $111m Series A funding.
Backers included Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.
The company intends to use the funds to further enhance its analytical speed and fortify its extensive collection of training and validation data sets, and expand its scientific and commercial teams to expedite the delivery of its pipeline of insights to the market.
Led by Grant Verstandig, Co-Founder and Executive Chairman, and Jeff Sherman, Co-Founder, Interim CEO, and Chief Technology Officer, Zephyr AI is developing improved data federation tools along with various machine learning algorithms in the areas of oncology and cardiometabolic disease. Through partnerships and proprietary data, the company is curating a comprehensive healthcare dataset and combining it with artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and generate ongoing research.
FinSMEs
13/03/2024